Statistical Analysis
tumor
REGRESSION, SECONDARY, TUMOR
For this retrospective secondary analysis performed from February 11 to 14, 2022, patients were divided into groups based on the presence or absence of LM and study treatments. Cohorts with and without LM were based on radiological findings at the time of study entry. Plasma tumor mutation burden (pTMB) was determined from blood samples collected prior to study therapy using a circulating tumor DNA assay (GuardantOMNI next-generation sequencing panel; Guardant Health Inc) and reported as mutations per megabase (Mb). Overall survival and PFS were analyzed according to intention to treat. Hazard ratios (HRs) and 90% CIs were calculated based on a stratified Cox proportional hazards regression model. A Cochran-Mantel-Haenszel test was used for the interaction in DCR among study groups. The presence of LM was assessed as a potential factor associated with OS, PFS, and DCR benefits using a test of interaction between treatment groups and the presence or absence of LM. Proportions between groups were compared with χ